证券之星消息，8月5日，马应龙（600993）融资买入2127.22万元，融资偿还1889.05万元，融资净买入 238.17万元，融资余额2.52亿元，近3个交易日已连续净买入累计1414.21万元，近20个交易日中有12个 交易日出现融资净买入。 融资融券余额2.54亿元，较昨日上涨1.0%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-05 | 2.54亿 | 252.55万 | 1.00% | | 2025-08-04 | 2.52亿 | 676.89万 | 2.76% | | 2025-08-01 | 2.45亿 | 533.93万 | 2.23% | | 2025-07-31 | 2.40亿 | -198.14万 | -0.82% | | 2025-07-30 | 2.42亿 | -551.73万 | -2.23% | 小知识 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-05 | 238.17万 | ...

Market Overview - The Shanghai Composite Index opened at 3615.81 points, down 0.05%, while the Shenzhen Component Index fell by 0.14% and the ChiNext Index decreased by 0.32% [1][7]. Education Sector Performance - The education sector experienced a short-term surge, with Angli Education hitting the daily limit up, while other companies like Kede Education, Action Education, Quanta Education, and Zhonggong Education also saw significant gains [2][3]. - Angli Education rose by 10.01%, Quanta Education increased by 1.74%, Action Education by 1.43%, Kede Education by 1.21%, Zhonggong Education by 0.67%, and Kevin Education by 0.56% [3]. Index Movements - The ChiNext Index turned positive after previously dropping over 0.32%, with the Shanghai Composite Index rising by 0.04% and the Shenzhen Component Index by 0.01% [4]. - The Shenzhen Component Index also reversed its earlier decline of over 0.18%, with the Shanghai Composite Index up by 0.05% and the ChiNext Index down by 0.09% [5]. - The Shanghai Composite Index initially fell over 0.09% before turning positive, while the Shenzhen Component Index dropped by 0.13% and the ChiNext Index by 0.2% [6]. Broader Market Trends - The A-share market opened with all three major indices declining, particularly in the AI industry chain, which saw widespread losses. However, sectors like high-speed rail and education showed positive performance [7].

当地时间8月5日，美股三大股指高开低走，此前因逢低买入推动的反弹告一段落。道指收跌61.9点，报44111.74点，跌幅为0.14%；纳指收跌137.03点，报 20916.55点，跌幅为0.65%；标普500指数收跌30.75点，报6299.19点，跌幅为0.49%。 大型科技股多数下跌，脸书跌逾1%，微软跌逾1%，英伟达跌近1%，苹果跌0.21%，谷歌跌0.19%，特斯拉跌0.17%，亚马逊涨近1%。 特朗普还表示，可能很快宣布美联储新任主席，未来美联储主席范围已缩小到四名候选人，其中不包括财政部长斯科特·贝森特。 医药赛道股多股大涨，辉瑞制药收盘大涨逾5%，联合健康集团大涨逾4%。 中概股涨跌不一，纳斯达克中国金龙指数跌0.56%。热门中概股方面，天境生物涨超15%，知乎涨逾6%，阿特斯太阳能涨超4%，新蛋涨逾4%，大全新能 源涨超3%。联掌门户跌近20%，百胜中国跌超6%，亚朵跌逾4%，霸王茶姬跌超3%，盛美半导体跌逾3%。 美债收益率普遍走高，基准的10年期美债收益率收报4.218%，对利率更加敏感的2年期美债收益率收报3.739%。 当地时间8月5日，美国总统特朗普在接受采访时表示，美国将首先对进 ...

Core Viewpoint - New Open Source Medical Technology Group Co., Ltd. has reported a decline in revenue and net profit for the first quarter of 2025, indicating potential challenges in its financial performance [1]. Financial Performance - As of the first quarter of 2025, the company reported total operating revenue of 325 million yuan, a year-on-year decrease of 17.69% [1]. - The net profit attributable to shareholders was 80.42 million yuan, down 33.75% year-on-year [1]. - The non-recurring net profit was 69.42 million yuan, reflecting a significant decrease of 44.85% year-on-year [1]. - The company's liquidity ratios are as follows: current ratio at 2.565 and quick ratio at 2.016, with a debt-to-asset ratio of 18.03% [1]. Market Activity - On August 5, 2025, the company's stock closed at 17.55 yuan, up 1.68%, with a turnover rate of 3.86% and a trading volume of 173,500 lots, amounting to a transaction value of 305 million yuan [1]. - The main funds experienced a net outflow of 23.43 million yuan, accounting for 7.68% of the transaction amount, with significant outflows from large and super-large orders [1]. Company Background - New Open Source Medical Technology Group Co., Ltd. was established in 2003 and is primarily engaged in the pharmaceutical manufacturing industry, located in Jiaozuo City [2]. - The company has a registered capital of 4.8605 billion yuan and a paid-in capital of 4.8470 billion yuan [1]. - The legal representative of the company is Zhang Junzheng [1]. Investment and Intellectual Property - The company has made investments in 19 enterprises and participated in 34 bidding projects [2]. - It holds 53 trademark registrations and 56 patent registrations, along with 95 administrative licenses [2].

华润三九属于医药制造行业，主要从事医药产品的研发、生产和销售。公司核心业务涵盖CHC健康消 费品和处方药领域，拥有覆盖全国的销售网络，与超过60万家药店保持合作。 8月1日，华润三九与博瑞医药就创新药BGM0504注射液达成合作协议。根据协议，华润三九将获得该 药物在中国大陆地区的研发、注册、生产及商业化权利。BGM0504是一种GLP-1和GIP受体双重激动 剂，目前正在进行III期临床试验，在降糖和减重效果上展现出优于同类产品的潜力。 8月5日主力资金净流出1877.29万元，占流通市值的0.04%。近五日主力资金累计净流入1.22亿元，占流 通市值的0.23%。 风险提示：医药研发存在不确定性，合作项目进展可能不及预期。 华润三九最新股价报32.16元，较前一交易日上涨0.12%。盘中最高触及32.28元，最低下探至31.82元， 成交金额达4.54亿元。 ...

Group 1 - The company has approved the appointment of an accounting firm for the special audit related to the issuance of A-shares in 2025 [1] - The board has also approved providing guarantees for its subsidiary, Guofa Pharmaceutical, which is seeking a loan of 20 million yuan from Postal Savings Bank [1] - Guofa Pharmaceutical aims to achieve sales revenue of no less than 381 million yuan in 2025 and is focused on turning losses into profits [1] Group 2 - The company has not disclosed the timeline or purpose for the upcoming capital increase, but it may strengthen its core business and explore new areas such as artificial intelligence [2] - The company plans to enhance the brand marketing of its "Haibao" eye drops, which is in a growing market, by increasing R&D investment and building automated production lines [2] - The chairman has recently visited a leading cloud-native operating system company, indicating potential new business expansion ideas [2]

Group 1 - The core viewpoint of the news is that Kunming Pharmaceutical Group Co., Ltd. has experienced a decline in both revenue and net profit in its latest quarterly report, indicating potential challenges in its financial performance [1][3] - As of August 5, 2025, the company's stock price closed at 14.75 yuan, down 1.14%, with a trading volume of 132,800 hands and a transaction amount of 196 million yuan [1] - The latest quarterly report shows total operating revenue of 1.608 billion yuan, a year-on-year decrease of 16.53%, and a net profit attributable to shareholders of 90.4823 million yuan, down 31.06% year-on-year [1] Group 2 - The company has made significant investments, with a total of 45 external investments and participation in 5,000 bidding projects [2] - In terms of intellectual property, the company holds 222 trademark registrations and 464 patents, along with 341 administrative licenses [2] - The company's financial ratios indicate a current ratio of 1.827, a quick ratio of 1.488, and a debt-to-asset ratio of 45.99% [1]

每经记者｜范芊芊 每经编辑｜董兴生 并购重组 嵘泰股份：拟以2.88亿元收购中山澳多51%股权 嵘泰股份公告称，公司拟使用自有资金2.88亿元收购中山市澳多电子科技有限公司（以下简称"中山澳 多"）51%股权，交易完成后，中山澳多将成为公司的控股子公司。本次交易构成关联交易，不构成重 大资产重组。交易价格以专业独立的第三方资产评估机构的评估价值为定价依据，并经双方协商一致确 定。 钧崴电子：全资子公司拟以26亿日元收购Flat Electronics Co.,Ltd.100%股权 海光信息：上半年归母净利润12.01亿元，同比增长41% 海光信息公告称，2025年上半年营业收入54.64亿元，同比增长45.21%；归母净利润12.01亿元，同比增 长40.78%。 东睦股份：上半年归母净利润为2.61亿元，同比增长37.61% 东睦股份公告称，上半年营业收入为29.30亿元，同比增长24.51%；归母净利润为2.61亿元，同比增长 37.61%。 中科曙光：上半年归母净利润同比增长29.89% 中科曙光发布业绩快报，上半年营业总收入为58.54亿元，同比增长2.49%；归属于上市公司股东的净利 润为7.31亿 ...

天眼查商业履历信息显示，通化金马药业集团股份有限公司，成立于1993年，位于通化市，是一家以从 事医药制造业为主的企业。企业注册资本96649.4707万人民币，实缴资本96649.4707万人民币。公司法 定代表人为张玉富。 通过天眼查大数据分析，通化金马药业集团股份有限公司共对外投资了25家企业，参与招投标项目5000 次，知识产权方面有商标信息57条，专利信息34条，此外企业还拥有行政许可258个。 来源：金融界 金融界消息 截至2025年8月5日收盘，通化金马（000766）报收于23.16元，上涨0.09%，换手率1.95%， 成交量18.81万手，成交金额4.36亿元。 资金流向方面，今日主力资金净流出2171.97万元，占比成交额4.99%。其中，超大单净流出1706.29万 元、占成交额3.92%，大单净流出465.69万元、占成交额1.07%，中单净流出流入755.59万元、占成交额 1.73%，小单净流入1416.38万元、占成交额3.25%。 通化金马最新一期业绩显示，截至2025一季报，公司营业总收入2.99亿元、同比增长1.25%，归属净利 润1158.28万元，同比增长26.09% ...

Group 1 - The company holds a 45% stake in Shandong Shengli Biological Engineering Co., Ltd., which operates in the pharmaceutical manufacturing industry [2] - The primary focus of Shandong Shengli is on bio-fermentation technology, producing animal-specific antibiotic raw materials, formulations, and feed additives [2] - The products are mainly applied in both terrestrial and aquatic animals [2]